



# Factors Affecting Cognitive Function in Patients with Stomach Cancer

Yu, Yeoung Ji<sup>1</sup> · Ahn, Seung Hee<sup>2</sup> · Cho, Yong Ae<sup>3</sup> · Ryu, Eunjung<sup>3</sup> · Kim, Eun-Ju<sup>4</sup>

<sup>1</sup>Department of Nursing, Graduate School of Chung-Ang University, Seoul; <sup>2</sup>Department of Nursing, National Cancer Center & Graduate School of Chung-Ang University, Seoul; <sup>3</sup>Department of Nursing, Chung-Ang University, Seoul; <sup>4</sup>Department of English, Hanyang Womens' University, Seoul, Korea

**Purpose:** This study aimed to identify factors affecting cognitive function in stomach cancer patients. **Methods:** This was a cross-sectional study designed to obtain data from stomach cancer patients. The Global Assessment of Recent Stress, Hospital Anxiety-Depression Scale, Distress Thermometer, Korean version of the Montreal Cognitive Assessment, and electronic medical records were used to assess stress, anxiety, depression, psychological distress, and cognitive function, respectively. **Results:** Among 182 total participants, there were statistically significant differences in sex between the group of patients who received chemotherapy and those who did not ( $\chi^2=5.32, p=.029$ ). There were statistically significant differences in stress and cognitive function between the two groups. The factors affecting cognitive function in stomach cancer patients included distress, stress, anxiety, and depression. **Conclusion:** Cognitive function should be examined with consideration of the psychological distress, stress, anxiety, and depression in patients with stomach cancer. Moreover, an improved program to manage cognitive function is needed, which includes mediation between psychological and physiological factors including stress, anxiety, and cognitive level.

**Key Words:** Drug Therapy, Stomach Neoplasms, Cognitive Dysfunction, Psychological Stress

## INTRODUCTION

According to incidence rates, stomach cancer is the fifth most common cancer worldwide and first and fourth among men and women, respectively, in Korea.<sup>1,2)</sup> The age-standardized rates for all-cancer incidence increased by 3.4% annually from 1999 to 2012, and then began to decrease from 2012 to 2015 (annual percent change, -6.1%).<sup>2)</sup> Stomach cancer was the most commonly diagnosed cancer in 2015, followed by colorectal, thyroid, lung, and breast cancer. However, stomach cancer started to decrease around 2011.<sup>2)</sup> Although the 5-year relative survival rates for stomach cancer increased in both sexes, from 42.8% in 1993~1995 to 75.4% in 2011~2015, the patients still complained of side effects such as nausea, vomiting, anorexia, diarrhea, fatigue,

anemia, and cognitive function changes.<sup>3,4)</sup> Patients with stomach cancer experience changes in cognitive function due to the course of chemotherapy.<sup>5)</sup> According to the conceptual model of change in cognitive function related to chemotherapy proposed by Hess and Insel in 2007, psychological factors such as stress, depression, anxiety, and distress and physiological factors such as neurotoxicity, anemia, cytokine, hormonal changes are involved in functional changes.<sup>6)</sup> Thus, cancer diagnosis and treatment affect not only physical but also psychological factors.<sup>7)</sup> These problems are important because they are related to mortality and suicide rates of cancer patients. The death rate is increased by 27% in cancer patients with distress, depression, anxiety, and poor quality of life.<sup>8)</sup> Among these factors, distress includes all psychological, social, and spiritually unpleasant emotional (both cognitive and behavioral) experiences, which reduce patient adaptation to cancer-related symptoms and treatment.<sup>9)</sup> This is a broad concept that includes anxiety and depression, while distress is reportedly caused by a wide variety of factors in cancer patients. Most studies on distress due to chemotherapy have been conducted in patients with breast cancer. These studies were likely easier to perform because of the high accessibility of breast cancer patients, who are mostly female, compared to that of patients with stomach cancer, with a higher incidence in men.

The present study is based on the model of change in cognitive function related to chemotherapy proposed by Hess and Insel.<sup>6)</sup> This

주요어: 항암화학요법, 위암, 인지손상, 심리적 스트레스

\*이 논문은 2014년도 정부(미래창조과학부)의 재원으로 한국연구재단의 지원을 받아 수행된 연구임(No. NRF-2014R1A2A2A01006008).

\*This research was supported by Basic Science Research Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Science, ICT and future Planning(NRF-2014R1A2A2A01006008).

Address reprint requests to: Ahn, Seung Hee

Department of Nursing, National Cancer Center  
323 Ilsan-ro, Ilsandong-gu, Goyang-si Gyeonggi-do 10408, Korea  
Tel: +82-32-920-0337 Fax: +82-32-920-1908 E-mail: sb-good@ncc.re.kr

Received: Nov 18, 2018 Revised: Dec 24, 2018 Accepted: Dec 25, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution NoDerivs License. (<http://creativecommons.org/licenses/by-nd/4.0/>) If the original work is properly cited and retained without any modification or reproduction, it can be used and re-distributed in any format and medium.

study aimed to assess differences in stress, psychological distress, anxiety, and depression between patients receiving and not receiving chemotherapy and to identify the factors affecting cognitive function in stomach cancer patients.

## METHODS

### 1. Design and sample

A descriptive survey with cross-sectional design was used to obtain data from stomach cancer patients in the National Cancer Center in 2016. The subjects included 182 stomach cancer patients who received and did not receive chemotherapy. The inclusion criteria included patients 18 years or older who had been diagnosed with stomach cancer, who were able to communicate, who understood the purpose of the study, and who agreed to participate in the study. Patients who were diagnosed with cancer other than stomach cancer and those who had no disease were excluded from the study.

The effect size of 0.5 with 80% power and a significance level of 0.05 required for independent sample t-tests using G\*POWER 3.1. The optimal sample number was 64 patients per group (128 total). An additional 20% was added to account for attrition. Therefore, the planned sample size was 156 participants.

### 2. Measures

The demographic characteristics of the participants used a questionnaire designed by the researchers through the literature review. The clinical information was about, pathological diagnosis, stage at diagnosis, and types of chemotherapy. All participants gave their informed consent to participate. Each participant's medical record was reviewed by the oncology nurse to validate their clinical characteristics.

Stress was measured using the Korean version of the Global Assessment of Recent Stress (GARS).<sup>10)</sup> This instrument contains a total of eight items with a score ranging from 0 to 72 points. A higher score indicates more serious stress. The Cronbach's  $\alpha$  of the Korean version of the GARS was .86.<sup>11)</sup> In this study, the Cronbach's  $\alpha$  was .80.

Patient anxiety and depression were measured using the Korean version of the Hospital Anxiety-Depression Scale (HADS).<sup>12,13)</sup> It consists of two subscales, which is a 14-item self-reported questionnaire designed to measure the level of anxiety and depression. Each seven items had been answered by the patient on a four-point Likert (0~3) scales. The HADS is scored by summing the ratings for the 7 items to

calculate subscale scores for anxiety and depression, respectively.<sup>12)</sup> In the present study, the Cronbach's  $\alpha$  of the HADS was .80 and .83 respectively.

The Distress Thermometer (DT) is a one-item self-report screening tool for measuring psychological distress in cancer patient.<sup>14)</sup> The instrument measures distress levels over the past week using an 11-point scale from 0 (no distress) to 10 (extreme distress) based on a thermometer-like Likert scale and a midpoint anchor labeled 'moderate distress'.<sup>14)</sup>

The original of the Montreal Cognitive Assessment (MoCA) is a neurocognitive test designed to screen for mild cognitive impairment.<sup>15)</sup> It scores from 0 to 30, where higher scores indicate better cognition and a score below 26 indicates cognitive impairment corresponding to mild cognitive impairment. The MoCA consists of 12 items and it can be administered in 10 minutes. In the MoCA-K, the words used in the short-term memory recall task and the letters used in the trail-making B task were changed, and the phonemic fluency task was replaced with a semantic fluency task.<sup>15)</sup> The internal reliability of MoCA-K was .84 in this study.

### 3. Data analysis

Descriptive statistics were conducted for socio-demographic and clinical characteristics. Independent t-tests and analysis of variance (ANOVA) were used to assess differences among the groups. Pearson's correlation coefficients were performed to assess the correlation among study variables. Hierarchical multiple regression analysis was performed to identify the factors that influenced distress in stomach cancer patients. All statistical tests were two-tailed, with  $p < .05$  indicating statistical significance. All analyses were conducted using SPSS 23.0 for Windows (IBM corporation, Chicago, USA).

### 4. Ethical considerations

This study was conducted after having obtained approval (NCC 2016-07-045-002) by the Institutional Review Board of the hospital for the ethical protection of study subjects. Informed consent was obtained from all participants. Confidentiality was ensured through a coding system, with numbers replacing the participants' names. When collecting the data, the participants received explanations about the purpose and procedures of the study. The participants were also informed that they could terminate their participation whenever they wished, that anonymity of study participants would be maintained.

## RESULTS

### 1. Sample characteristics

The study participants comprised 182 stomach cancer patients: 123 (67.6%) of patients who received chemotherapy and 59 (32.4%) with no chemotherapy. Participants characteristics are displayed in Table 1. There was statistical significance in sex between the two groups ( $\chi^2=5.32$ ,  $p=.029$ ). Of the participants, 92 (74.8%) were diagnosed with stage 3 over in the chemotherapy group, while 8 (13.5%) in the non-chemotherapy group. There were significant associations in disease stage ( $\chi^2=112.26$ ,  $p<.001$ ) between two groups (Table 1).

### 2. Descriptive statistics of the study variables and group differences.

Table 2 show descriptive statistics for the stress, distress, depression and anxiety, and cognitive function. There were significant differences in psychological distress and cognitive function between patients

receiving and not receiving chemotherapy. The mean score of stress was statistical significance in the two group ( $t=-2.65$ ,  $p=.009$ ). The mean score of cognitive function in the chemotherapy group was 21.53, which was lower than that of the non-chemotherapy group ( $t=-2.86$ ,  $p=.005$ ).

### 3. Correlations among study variables

A statistically significant negative correlation was observed for the relationship between cognitive function and stress, anxiety, depression, and psychological distress ( $r=-.29$ ,  $p=.001$ ). There were positive correlations with stress ( $r=.41$ ,  $p<.001$ ), anxiety ( $r=.34$ ,  $p<.001$ ), and depression ( $r=.33$ ,  $p<.001$ ). Thus, the lower the cognitive function, the higher the psychological distress; similarly, the higher the level of stress, anxiety, and depression, the higher the level of psychological distress (Table 3).

**Table 1.** Demographic and Clinical Characteristics of Sample

(N = 182)

Variables	Categories	Chemotherapy group (n=123)	Non-chemotherapy group (n=59)	$\chi^2$	df	p
		n (%)	n (%)			
Sex	Male	88 (71.5)	32 (54.2)	5.32	1	.029
	Female	35 (28.5)	27 (45.8)			
Age (year)	< 39	7 (5.7)	-	5.63	5	.344
	40~49	24 (19.5)	10 (15.0)			
	50~59	30 (24.4)	13 (19.4)			
	60~69	31 (25.2)	22 (32.8)			
	≥ 70	31 (25.2)	22 (32.8)			
Education	Elementary school	12 (9.8)	9 (15.2)	1.47	3	.690
	Middle school	24 (19.7)	9 (15.2)			
	High school	49 (40.2)	24 (40.8)			
	≥ College	37 (30.3)	17 (28.8)			
Marital status	Single	16 (13.1)	3 (5.1)	3.08	2	.214
	Married	100 (80.2)	54 (91.5)			
	Others	6 (4.9)	2 (3.4)			
Cohabitation type	Alone	25 (20.3)	12 (20.7)	1.30	3	.729
	Spouse	38 (30.9)	18 (31.0)			
	Spouse and child	40 (32.5)	22 (37.9)			
	Others	20 (16.3)	6 (10.4)			
Stage at diagnosis	Stage I	7 (5.7)	49 (83.1)	112.26	3	< .001
	Stage II	24 (19.5)	2 (3.4)			
	Stage III	55 (44.7)	6 (10.1)			
	Stage IV	37 (30.1)	2 (3.4)			
Duration of chemotherapy (year)	< 1	84 (70.6)				
	1~2	20 (16.8)				
	2~3	7 (5.9)				
	≥ 3	8 (6.7)				
Type of chemotherapy regimen	5-FU	44 (35.8)				
	Herceptin	44 (35.8)				
	Others	35 (28.4)				

#### 4. Factors affecting cognitive function in patients with stomach cancer

Hierarchical multiple regression analysis was conducted to identify predictors of cognitive function in patients with stomach cancer (Table 4). Potential confounding variables were minimally controlled for age, gender, and chemotherapy in the first model (model 1). The second model (model 2) was adjusted for the variables in model 1 plus stress, psychological distress, anxiety, and depression. The factors affecting cognitive function in patients with stomach cancer included age ( $B = -.18, p < .001$ ), chemotherapy ( $B = -3.09, p < .001$ ), and psychological distress ( $B = -.38, p = .036$ ).

#### DISCUSSION

This study was carried out to manage change of cognitive function by analyzing the factors affecting this cognitive function in stomach cancer patients based on the literature review and Hess and Insel<sup>6)</sup> model of change of cognitive function related to chemotherapy. The study population was similar to a previous study in that the average patient age was 50 years or older and the incidence of stomach cancer was higher in men than that in women.<sup>16)</sup> Stomach cancer patients who did not receive chemotherapy had higher stress scores than those in patients who received chemotherapy. This is because the quality of life experienced by stomach cancer patients due to gastrectomy,

**Table 2.** Differences in Variables according to Chemotherapy Status (N = 182)

Variables	Chemotherapy	Non-chemotherapy	t	p
	M ± SD	M ± SD		
Psychological distress	3.76 ± 2.16	4.37 ± 2.77	-1.51	.135
Stress	19.38 ± 11.13	25.10 ± 14.68	-2.65	.009
Anxiety	4.90 ± 3.63	6.14 ± 4.68	-1.78	.078
Depression	7.80 ± 4.11	7.49 ± 3.57	0.50	.610
Cognitive function	21.53 ± 5.30	23.85 ± 4.74	-2.86	.005

**Table 3.** Correlations among Study Variables (N = 182)

Variables	Psychological distress	Cognitive function	Stress	Anxiety	Depression
	r (p)	r (p)	r (p)	r (p)	r (p)
Psychological distress	1				
Cognitive function	-.29 (.001)	1			
Stress	.41 (< .001)	.05 (.613)	1		
Anxiety	.34 (< .001)	-.13 (.145)	.54 (< .001)	1	
Depression	.33 (< .001)	-.29 (.001)	.35 (< .001)	.35 (< .001)	1

**Table 4.** The Predictor of Cognitive Function in Patients with Stomach Cancer (N = 182)

Variables	Model 1				Model 2			
	B	SE	t	p	B	SE	t	p
Age	-0.19	0.03	-6.61	< .001	-0.18	0.03	-5.92	< .001
Gender (female vs. male)	0.16	0.73	0.22	.830	-0.23	0.75	0.29	.770
Chemotherapy (non-CT vs. CT)	-3.12	0.75	-4.16	< .001	-3.09	0.76	-4.06	< .001
Psychological distress					-0.38	0.18	-2.11	.036
Stress					0.05	0.04	1.14	.254
Anxiety					-0.13	0.12	-1.09	.279
Depression					-0.11	0.10	-1.06	.292
	R <sup>2</sup> = .24, Adj.R <sup>2</sup> = .22, F <sub>(3,179)</sub> = 18.49, p < .001				R <sup>2</sup> = .29, Adj.R <sup>2</sup> = .26, F <sub>(7,175)</sub> = 9.85, p < .001			

CT= chemotherapy; Female= 0; Non-chemotherapy= 0.

negative body image, and changes in life processed greatly affect their stress.<sup>17)</sup>

In this study, stomach cancer patients who received chemotherapy had lower level of stress. The patients also had a lower cognitive function score than those who did not receive chemotherapy. This finding is consistent with the results that there is cognitive impairment, such as impairment of performance, concentration, memory, language memory, and recall memory area, in colorectal cancer and breast cancer patients receiving chemotherapy.<sup>18)</sup>

Breast cancer patients who received chemotherapy with doxorubicin, cyclophosphamide, and taxane over six months had changes in their cognition, such as decreased attention and memory, and symptoms of anxiety, depression and fatigue.<sup>19)</sup> Because these factors have a negative impact on the physical, psychological, and cognitive functions of cancer patients receiving chemotherapy, they increase an unpleasant emotional experience for cancer-related symptoms and treatment.<sup>20)</sup> Since most cancer patients are focused on physical symptoms, and psychological symptoms such as depression and stress are being ignored in the treatment process.<sup>21)</sup> In this study, patients were more likely to be exposed to emotional problems. They need to be actively concerned about the psychological symptoms that are as important as the patient's physical symptoms and manage these symptoms through periodic interviews. Patients with stomach cancer receiving chemotherapy have problems with anorexia, headache, vomiting, malnutrition, and weight loss.<sup>22)</sup> Anorexia and malnutrition cause anemia and fatigue and these physical problems seriously affect cognition, emotion, and psychological well-being.<sup>23)</sup> Cancer patients experience physical and psychological distress due to these problems.<sup>24)</sup> According to previous studies, individual nutritional management for stomach cancer patients receiving chemotherapy is needed to manage their psychological distress and individualized exercise prescriptions and physical activities are needed for the treatment of fatigue.

In this study, age, chemotherapy, and psychological distress increased vulnerability to cognitive function in stomach cancer patients. Psychological distress had a partial mediating effect in the relationship between self-reported cognitive decline and quality of life in colon cancer patients.<sup>25)</sup> Therefore, distress in cancer patients should be categorized through active screening and appropriate treatment services should be provided to patients who require an intervention. Although evidence of chemotherapy induced impairments in cognitive function does exist, there is still much to be discovered. More studies are needed

to further elucidate the phenomenon of chemotherapy induced cognitive dysfunction and to describe its characteristics (e.g., onset, duration).<sup>26)</sup>

This study was subject to several limitations. First, all the participants were stomach cancer patients at a cancer hospital, which limits the generalizability of the study results. Second, since cross-sectional studies were performed, studies should be conducted to verify the presence of distress over the duration of chemotherapy. Despite these limitations, the merit of this study is that we measured cognitive function changes using the MoCA-K, a standard tool for screening for mild cognitive impairment. The MoCA-K has a strength to integrate cognitive functions of various domains.<sup>27)</sup> Changes in cognitive function related to chemotherapy have been subjective and measured using insensitive tools, although patient symptoms may be minimal.<sup>28)</sup>

## CONCLUSIONS

This study used the conceptual model described by Hess and Insel to examine the effect of chemotherapy on cognitive function in patients with stomach cancer. Psychological distress is important factor affecting cognitive function; therefore, these factors should be accurately measured and assessed to manage distress caused by chemotherapy among patients with stomach cancer.

As the number of stomach cancer survivors grows, they have gained the attention in the healthcare system. Survivors' reports about their experience of late effects either from the stomach cancer or its chemotherapy now suggest the needs for the related care within the healthcare system. When the proper care for chemotherapy related toxicity and psychological distress is provided, the quality of survivors' life would be enhanced and their emotional stability would be ensured as well.

## ORCID

유영지 [orcid.org/0000-0002-8362-9124](https://orcid.org/0000-0002-8362-9124)

안승희 [orcid.org/0000-0001-6461-3381](https://orcid.org/0000-0001-6461-3381)

조용애 [orcid.org/0000-0003-3501-144X](https://orcid.org/0000-0003-3501-144X)

류은정 [orcid.org/0000-0002-2232-6082](https://orcid.org/0000-0002-2232-6082)

김은주 [orcid.org/0000-0002-3929-2720](https://orcid.org/0000-0002-3929-2720)

## REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136:E359-86.
2. Jung KW, Won YJ, Kong HJ, Lee ES. Community of Population-Based Regional Cancer Registries. *Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015*. *Cancer Res Treat*. 2018;50:303-16.
3. Kim JH. Influencing factors on depression in stomach cancer patients receiving chemotherapy. *Korean J Adult Nurs*. 2012;24:588-96.
4. Shim EJ, Shin YW, Jeon HJ, Hahm BJ. Distress and its correlates in Korean cancer patients: pilot use of the distress thermometer and the problem list. *Psychooncology*. 2008;17:548-55.
5. Gehring K, Roukema JA, Sitskoorn MM. Review of recent studies on interventions for cognitive deficits in patients with cancer. *Expert Rev Anticancer Ther*. 2012;12:255-69.
6. Hess LM, Insel KC. Chemotherapy-related change in cognitive function: a conceptual model. *Oncol Nurs Forum*. 2007;34:981-94.
7. Yi MS, Kim JH, Park EY, Kim JN, Yu ES. Focus group study on psychosocial distress of cancer patients. *J Korean Acad Adult Nurs*. 2010;22:19-30.
8. Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? *Nat Clin Pract Oncol*. 2008;5:466-75.
9. Wood DE. National Comprehensive Cancer Network (NCCN) clinical practice guidelines for lung cancer screening. *Thorac Surg Clin*. 2015;25:185-97.
10. Koh KB. Stress perception of patients with psychosomatic disorders. *J Korean Neuropsychiatr Assoc*. 1988;27:514-24.
11. Koh KB, Park JK. Validity and reliability of the Korean version of the global assessment of recent stress scale. *Korean J Psychosom Med*. 2000;8:201-11.
12. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 1983;67:361-70.
13. Oh SM, Min KJ, Park DB. A study on the standardization of the hospital anxiety and depression scale for Koreans: a comparison of normal, depressed and anxious groups. *J Korean Neuropsychiatr Assoc*. 1999;38:289-96.
14. Holland JC. Update: NCCN practice guidelines for the management of psychosocial distress. *Oncology*. 1999;13:459-507.
15. Lee JY, Lee DW, Cho SJ, Na DL, Jeon HJ, Kim SK, et al. Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal Cognitive Assessment. *J Geriatr Psychiatry Neurol*. 2008;21:104-10.
16. Jeon MK, Park GJ. Development of a self-care performance scale for patients with stomach cancer after gastrectomy. *Asian Oncol Nurs*. 2016;16:67-74.
17. Lee KE, Son YG. Research trends of quality of life after gastrectomy among gastric cancer patients in Korea. *Asian Oncol Nurs*. 2016;16:59-66.
18. Krynetskiy E, Krynetskaia N, Rihawi D, Wiczerzak K, Ciummo V, Walker E. Establishing a model for assessing DNA damage in murine brain cells as a molecular marker of chemotherapy-associated cognitive impairment. *Life Sci*. 2013;93:605-10.
19. Jansen CE, Cooper BA, Dodd MJ, Miasowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. *Support Care Cancer*. 2011;19:1647-56.
20. Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. *Breast Cancer Res Treat*. 2008;110:143-52.
21. Fulcher CD, Badter T, Gunter AK, Marrs JA, Reese JM. Putting evidence into practice: interventions for depression. *Clin J Oncol Nurs*. 2008;12:131-40.
22. Jo KS, Ban JY, Yoon JY, Kook SH, Yoon HS, Yoo YS. Quality of life in patients with multiple myeloma. *Korean J Adult Nurs*. 2016;28:314-22.
23. Hoffman AJ, von Eye A, Gift AG, Given BA, Given CW, Rotherth M. The development and testing of an instrument for perceived self-efficacy for fatigue self-management. *Cancer Nurs*. 2011;34:167-75.
24. Kwon EJ, Yi M. Distress and quality of life in breast cancer survivors in Korea. *Asian Oncol Nurs*. 2012;12:289-96.
25. Jansen CE, Miasowski C, Dodd M, Dowling G, Kramer J. A meta-analysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. *Cancer*. 2005;104:2222-33.
26. Oh PJ, Kim JH. Chemotherapy-related cognitive impairment and quality of life in people with colon cancer: the mediating effect of psychological distress. *J Korean Acad Nurs*. 2016;46:19-28.
27. Choi CH, Park S, Park HJ, Cho Y, Sohn BK, Lee JY. Study on cognitive reserve in Korea using Korean version of Cognitive Reserve Index Questionnaire. *J Korean Neuropsychiatr Assoc*. 2016;55:256-63.
28. Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. *Cancer Treat Rev*. 2012;38:926-34.